INZY 5.50 Inozyme Pharma, Inc.
| Range: | 2.689-7.795 | Vol Avg: | 246592 | Last Div: | 0 | Changes: | 0.39 |
| Beta: | 1.51 | Cap: | 0.35B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Jul 24 2020 | Empoloyees: | 59 | ||
| CUSIP: | 45790W108 | CIK: | 0001693011 | ISIN: | US45790W1080 | Country: | US |
| CEO: | Dr. Douglas A. Treco Ph.D. | Website: | https://www.inozyme.com | ||||
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow